Avi Eliahu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Avi Eliahu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Ariel Muliadi
Respira Therapeutics, Inc., Burlingame, CA, United States
1 shared publicationAudrey E. Weers
Respira Therapeutics, Inc., Burlingame, CA, United States
1 shared publicationDanforth P. Miller
Respira Therapeutics, Inc
1 shared publication- David F. Choy
Genentech, Inc., South San Francisco, California; and
1 shared publication - Hallam Gugelmann
Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA
1 shared publication - Hubert Chen
Vanderbilt University
1 shared publication
Latest Publications
- 26 May 2022
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 75, 102133
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
- 26 May 2022
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 75, 102133
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation
- Open Access
- 15 March 2022
- Published by Frontiers Media SA in Frontiers in Drug Delivery
- Vol. 2
Formulation of Dry Powders for Inhalation Comprising High Doses of a Poorly Soluble Hydrophobic Drug
Spray-dried formulations of a hydrophobic, crystalline drug, GDC-A, were prepared using the suspension-PulmoSphere™ technology. Increases in drug loading resulted in decreases in the primary particle size distribution and increases in tapped density. This enabled fine particle doses of up to 25 mg to be achieved with a portable dry powder inhaler from a size three capsule. The powders were physically and chemically stable, with no changes in physical form or degradants observed during processing or on storage in an open configuration at 40°C for 1 month. The potential benefits of the suspension-based spray drying process relative to solution-based spray drying in terms of stability, lung targeting, and safety/tolerability are discussed.
- 15 March 2022
- Published by Frontiers Media SA in Frontiers in Drug Delivery
- Vol. 2
Open AccessFormulation of Dry Powders for Inhalation Comprising High Doses of a Poorly Soluble Hydrophobic Drug
Spray-dried formulations of a hydrophobic, crystalline drug, GDC-A, were prepared using the suspension-PulmoSphere™ technology. Increases in drug loading resulted in decreases in the primary particle size distribution and increases in tapped density. This enabled fine particle doses of up to 25 mg to be achieved with a portable dry powder inhaler from a size three capsule. The powders were physically and chemically stable, with no changes in physical form or degradants observed during processing or on storage in an open configuration at 40°C for 1 month. The potential benefits of the suspension-based spray drying process relative to solution-based spray drying in terms of stability, lung targeting, and safety/tolerability are discussed.